Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma. by Tsai, J. F. et al.
Britfsh Journal of Cancer (1995) 72, 442-446
©) 1995 Stockton Press All rights reserved 0007-0920/95 $12.00
Clinical evaluation of serum a-fetoprotein and circulating immune
complexes as tumour markers of hepatocellular carcinoma
JF Tsai', JE Jeng2, MS Ho3, WY Chang', ZY Lin' and JH Tsai'
c}
'Department ofInternal Medicine and 2Clinical Laboratory, Kaohsiung Medical College; 3Institute ofBiomedical Sciences,
Academia Sinica, Taiwan, Republic ofChina.
Summary To evaluate the diagnostic application of serum a-fetoprotein (AFP) and circulating immune
complexes (CICs), AFP, 3% polyethylene glycol (PEG)-CICs, 4% PEG-CICs, and Clq-CICs were determined
in 101 patients with cirrhosis alone, 101 sex-matched and age-matched cirrhotic patients with hepatocellular
carcinoma (HCC) and 54 healthy controls. Multivariate analysis indicated that AFP (odds ratio 1.014; 95%
confidence interval 1.004-1.024) and 3% PEG-CICs (odds ratio 1.011; 95% confidence interval 1.005-1.017)
are associated, in a dose-related fashion, with an increased risk for HCC. A receiver operative characteristic
(ROC) curve was used to determine the optimal cut-off values of AFP (120 ng ml-') and 3% PEG-CICs
(310 jg aggregated IgG equivalent ml-'). The area under ROC curve was 0.875 for AFP and 0.812 for 3%
PEG-CIC. Both AFP and 3% PEG-CICs show a high specificity (100%) and positive likelihood ratio. The
sensitivity was 65.3% for 3% PEG-CICs and 67.3% for AFP. Determination of both markers in parallel
significantly increase the diagnostic accuracy (92.1%) and sensitivity (84%), with a high specificity (100%) and
positive likelihood ratio (>84). In conclusion, both 3% PEG-CICs and AFP are independent risk factors of
HCC, and may be used as complementary tumour markers to discriminate HCC from cirrhosis. Determina-
tion of 3% PEG-CICs should be performed in cirrhotics negative for AFP to improve detection of
HCC.
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Hepatocellular carcinoma (HCC) appears to be associated
with hepatitis B and C virus infection and is common in
patients with cirrhosis caused by chronic viral hepatitis (Jeng
and Tsai, 1991; Simonetti et al., 1991; Tsai et al., 1993,
1994a-fl. HCC usually presents late, and patients are
generally in poor clinical condition when diagnosed. An
effective screening system to detect HCC at an early stage
may result in more effective treatment. The lack of symptoms
in the early stage of HCC makes screening of patients at risk
for HCC impractical. a-Fetoprotein (AFP) is an oncofetal
protein produced by HCC. Although the role of AFP in the
diagnosis of advanced HCC is well recognised, at least one-
third of small HCCs and 10% of advanced HCCs will be
missed unless another diagnostic tool is used (Chen and
Sung, 1977; Lee et al., 1991; Sherlock and Dooley, 1993; Tsai
et al., 1994b). In addition, AFP may be increased in non-
malignant liver disease (Chen and Sung, 1977; Sherlock and
Dooley, 1993). These shortcomings have motivated many
investigators to search for other better tumour markers for
HCC.
There is increasing evidence that experimental tumour-
bearing animals and patients with cancer have increased
levels of circulating immune complexes (CICs) (Brown et al.,
1983, 1984; Neri, 1983; Salinas et al., 1983; Coursaget et al.,
1986; Tsai et al., 1990a, 1991; Tabor, 1991). The finding of a
correlation between CIC levels and extent of tumour burden
led to the expectation that determination of CIC levels might
be useful in monitoring the clinical course of the disease
(Neri, 1983; Salinas et al., 1983; Brown et al., 1984; Tsai et
al., 1991). CICs have been shown in patients with HCC
(Brown et al., 1983, 1984; Coursaget et al., 1986; Tsai et al.,
1990a, 1991; Tabor, 1991) and could be used as a marker to
monitor therapy in HCC (Tsai et al., 1991). However, the
role of CICs as a diagnostic marker has never been clearly
elucidated.
Liver cirrhosis (LC) is considered to be a premalignant
condition of HCC. Between 2.2% and 55% of autopsied
cirrhotics have HCC, and about 80% of HCC patients have
associated cirrhosis (Tsai et al., 1990a, 1991, 1994a,c,ef; Jeng
and Tsai, 1991; Simonetti et al., 1991; Sherlock and Dooley,
1993). Thus, early detection of HCC in patients with LC is
important. This study determines the diagnostic efficacy of
CICs and AFP for detection of HCC in cirrhotic
patients.
Subjects and methods
Study population
The study population comprised 101 consecutive cirrhotic
HCC patients and 101 sex-matched and age-matched (± 5
years) patients with cirrhosis alone. LC was
clinicopathologically proven, HCC was diagnosed by liver
biopsy or aspiration cytology. Only patients without previous
history of treatment were enrolled and serum samples col-
lected before treatment were used for analysis. In patients
with HCC, there were 92 men and nine women, with ages
ranging from 26 to 87 (median 57) years. Hepatitis B surface
antigen (HBsAg) was positive in 82 HCC patients and in
another 84 patients with cirrhosis alone. Antibody to
hepatitis C virus (anti-HCV) was positive in 28.7% of
patients with HCC and 25.7% of patients with cirrhosis
alone. Another 54 HBsAg-negative and anti-HCV-negative
community healthy adults were enrolled as healthy controls.
Forty-six of them were males and the other eight were
females. Their ages ranged from 24 to 74 (median 55) years.
The median age and sexual distribution was without
significant difference among these three groups. There was no
space-occupying lesion in LC patients and healthy controls as
evidenced by normal abdominal sonography. All healthy
controls had normal serum transaminase levels. All the
patients and controls were enrolled during the same period
and all gave informed consent to participate in the study,
which was approved by the investigation and ethics commit-
tee of the hospital.
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The double-concentration method of precipitation of CICs
by polyethylene glycol (PEG) was modified from Manger et
al. (1985) and Fust et al. (1980). Briefly, ml of 6% PEG-
6000 in phosphate-buffered saline (PBS) pH 7.0 was added to
the plastic tube containing 0.2 ml of serum in 0.8 ml of 0.1 M
PBS to make a final concentration of 3% PEG. After incuba-
tion for 18 h at 4°C, the tubes were centrifuged at 1000 g for
20 min at 4°C. The supernatant was removed and saved for
determination of 4% PEG-precipitable immune complexes
(4% PEG-CICs). The pellet was washed twice with 3% PEG
in PBS. A 200 gil volume of PBS was added to dissolve the
final precipitate and the protein concentration was measured
spectrophotometrically at 280 nM. The saved supernatant was
precipitated with adequate volume of 6% PEG to make a
final concentration of 4% PEG, incubated at 4°C for 18 h,
and then centrifuged at 1000 g for 20 min at 4°C. The
precipitate was washed twice with 4% PEG in PBS. The final
pellet was dissolved in 0.2 ml of PBS. The absorbance at
280 nM was measured. For preparing the standard curve,
purification and aggregation of IgG were according to the
method of Fields et al. (1982) and McCarthy et al. (1981)
respectively. The starting aggregated immunoglobulin (AIgG)
preparation was adjusted to 500 gLg ml-' with normal human
serum, then serial 2-fold dilutions were made in PBS. The
following procedures were the same as described previously.
The results were expressed as gLg equivalents of AIgG per ml
(gig AIgG equiv. ml-).
The Clq binding CICs (Clq-CICs) solid phase enzyme
immunoassay was detected by a commercial immune com-
plex microassay (Diamedix Corporation, Miami, FL, USA).
The results were expressed as gig AIgG equiv. ml-'.
Serological examination
Serum was tested for HBsAg and AFP (Ausria II and a-Feto
Riabead, Abbott Laboratories, Chicago, IL, USA). Anti-
HCV was detected with Abbott HCV EIA second generation
(Abbott Laboratories). Conventional liver function tests were
measured by sequential multiple autoanalyser.
Statistical analysis
The Mann-Whitney U-test was used to compare the
difference between medians of continuous variables. The rela-
tionships between continuous variables were analysed by
Spearman rank correlation. Frequencies of positivity were
compared by chi-square test with Yates' correction. Stepwise
logistic regression was used for multivariate analysis. The
significance level was set at P-value less than 0.05.
Sensitivity, specificity, positive and negative predictive
value, positive and negative likelihood ratio and diagnostic
accuracy were calculated according to the following formula
(Sox et al., 1989):
Sensitivity = a/(a + c)
Specificity = d/(b + d)
Accuracy = (a + d)/(a + b + c + d)
Positive predictive value = a/(a + b)
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Negative predictive value = d/(c + d)
Positive likelihood ratio = sensitivity/(l- specificity)
Negative likelihood ratio = (1- sensitivity)/specificity
where a = true-positive cases, b = false-positive cases,
c = false-negative cases and d = true-negative cases.
Receiver operating characteristic (ROC) curves were con-
structed by calculating the sensitivities and specificities of
AFP or CIC assays at several cut-off points. The differences
in diagnostic accuracy between the marker tests were
measured by McNemar's test.
Results
CIC levels in patients with HCC, LC and controls
As shown in Table I, the levels of Clq-CICs and 3% PEG-
CICs in patients with HCC were higher than in controls
(P<0.0001). The 4% PEG-CIC level was lower in the former
than that in the latter (P<0.01). Patients with HCC also had
significantly higher levels of 3% PEG-CICs and 4% PEG-
CICs when compared with LC patients (P<0.001 and
P<0.01 respectively). There were positive correlations
between 3% PEG-CICs and prothrombin time (r = 0.32,
P<0.01), globulin (r = 0.39, P<0.0001), total and direct
bilirubin (r= 0.54, P<0.0001, and r=0.53, P<0.0001,
respectively), y-glutamyltranspeptidase (r = 0.35, P<0.001)
and alanine transaminase (r = 0.24, P<0.05). There were
negative correlations between 3% PEG-CICs and albumin
(r=-0.21, P<0.04). There was a positive correlation
between 4% PEG-CICs and globulin (r = 0.43,
P<0.0001).
In patients with LC, the level ofClq-CICs was higher than
in controls (P<0.0001), while the 4% PEG-CIC level was
lower than in controls (P<0.0001). There was no difference
in the 3% PEG-CICs between LC patients and controls
(Table I).
AFP levels in patients with HCC, LC and controls
The median level of AFP in patients with HCC (750; range
3-629 610 ng ml-') was significantly higher than that in
patients with cirrhosis alone (median 3.7, range
3-110 ng ml') or controls (median 3.0; range
3.0-5.1 ng ml-') (each P<0.0001). The upper limit of nor-
mal AFP was defined as 20 ngml-' (Chen and Sung, 1979;
Sherlock and Dooley, 1993). Serum AFP in all controls was
lower than 20ngml-'. Sixteen (15.8%) patients with cirr-
hosis alone and 77 (76.2%) patients with HCC had an AFP
level greater than 20 ngml-'. In patients with cirrhosis alone,
there was positive correlation between AFP and 3% PEG-
CICs (r = 0.23, P<0.002), AFP and 4% PEG-CICs
(r = 0.22, P<0.030), AFP and Zy-glutamyltranspeptidase
(r = 0.33, P<0.001). In patients with HCC, AFP was
positively correlated with 4% PEG-CICs (r = 0.22,
P<0.003). There was no correlation between AFP and 3%
PEG-CICs or Clq-CICs (data not shown).
Table I Circulating immune complexes in patients with liver cirrhosis, cirrhotic hepatocellular carcinoma and controls
CIC (jig AIgG equiv. ml-))a
3% PEG-CICs 4% PEG-CICs Clq-CICs
HCC (n = 101) 381.8 (79.7-1480.3) 62.2 (4.3-284.5) 20.3 (6.8-78.6)
LC (n = 101) 245.3 (34.7-308.4) 30.2 (5.7-113.7) 17.3 (9.5-58.1)
Control (n = 54) 187.3 (60.3-558.6) 82.1 (9.2-274.3) 8.6 (3.2-16.5)
P-value: Mann-Whitney U-test)
HCC vs LC <0.001 <0.01 NS
HCC vs control <0.0001 <0.01 <0.0001
LC vs control NS <0.0001 <0.0001
CIC, circulating immune complexes; PEG, polyethyleneglycol; LC, liver cirrhosis; HCC, hepatocellular carcinoma; NS, non-significant. aData
were expressed as median value with ranges in parentheses.AFP and CIC astumour markers of HCC
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AFP and 3% PEG-CICs as riskfactorsfor HCC
In order to adjust the influence of impaired liver function on
CIC and AFP levels, stepwise logistic regression was used for
multivariate analysis. Dependent variable was the status of
HCC existence. Independent variables included AFP, CICs,
albumin, globulin, direct and indirect bilirubin, transaminase
and y-glutamyltranspeptidase. Only 3% PEG-CICs and AFP
were found to be associated, in a dose-related fashion, with
an increased risk for developing HCC (odds ratio = 1.011,
P<0.0001, for 3% PEG-CIC and 1.014, P<0.0001, for
AFP) (Table II).
CICs and AFP as diagnostic markersfor HCC evaluated by
ROC curve
As 3% PEG-CICs and AFP were related to the development
of HCC, an attempt was made to differentiate cirrhotic HCC
from cirrhosis alone by these two markers. ROC curves for
3% PEG-CICs and AFP are shown in Figure 1. The cal-
culated area under the ROC curve is 0.875 for AFP and
0.812 for 3% PEG-CICs. The sensitivity of each marker was
determined at several specificity levels. The corresponding
sensitivities and actual cut-off points producing Figure 1 are
given in Table III. The optimal cut-off values selected by
ROC curves were 310tLg AIgG equiv. ml' for 3% PEG-
CICs and 120tgml-' for AFP. The calculated sensitivities,
specificies, accuracies, positive and negative predictive values
and positive and negative likelihood ratios are shown in
Table IV.
According to the ROC analysis, the optimal cut-off level
for AFP was 120 .tg ml-', since up to this level the specificity
improved without essentially decreasing the sensitivity, the
resulting specificity being 100% and sensitivity 67.3%, with a
diagnostic accuracy of 83.6%, a positive likelihood ratio
greater than 67 and a negative likelihood ratio of 0.32 (Table
IV). On the other hand, the recommended diagnostic level of
HCC in Chinese was 400ngml-l (Chen and Sung, 1977).
Using 400 ng ml-' as cut-off value, the sensitivity decreased
to 63.7% but the specificity was still 100%. There was no
significant difference between the diagnostic accuracies cal-
culated from these two cut-off values (Table IV).
In the ROC analysis, the optimal cut-off value for 3%
PEG-CICs was 310 tg AIgG equiv.ml1', which gave a
specificity of 100% at sensitivity level of 65.3%. The cal-
culated diagnostic accuracy and positive and negative
likelihood ratios were 82.6%, >65 and 0.34 respectively
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Figure 1 The value of serum a-fetoprotein (AFP) and 3%
polyethylene glycol circulating immune complexes (3% PEG-
CICs) in the diagnosis of hepatocellular carcinoma among 101
patients with cirrhotic hepatocellular carcinoma and 101 patients
with cirrhosis alone as analysed with the help of receiver
operative characteristic (ROC) curves. The area under ROC
curve was 0.875 for AFP (-) and 0.812 for 3% PEG-CICs
(0).
Table II Risk of hepatocellular carcinoma evaluated by stepwise logistic regression analysis of the comparison between patients with cirrhotic
hepatocellular carcinoma and those with cirrhosis alone
Regression Standard Odds ratio
Variables coefficient error P-value (95% confidence interval)
a-Fetoprotein 0.014 0.005 <0.001 1.014 (1.004-1.024)
3% PEG-CICs 0.011 0.003 <0.001 1.011 (1.005-1.017)
Indirect bilirubin - 0.371 0.074 <0.001 0.689 (0.579-0.794)
3% PEG-CICs, 3% polyethylene glycol-precipitable circulating immune complexes.
Table III The sensitivities and corresponding cut-off values and diagnostic accuracies for 3% PEG-CICs, and a-fetoprotein in the detection of
hepatocellular carcinoma at specificity levels between 40 and 100%
Specificity (%)
100 100 95 90 85 80 70 60 40
Sensitivity (%) AFP 63.3 67.3 70.3 72.2 76.2 83.1 86.1 88.1 88.6
Cut-off (ngml ') 400 120a 83 40 22 8 5 4 3
Accuracy (%) 81.7 83.6 83.2 82.1 80.2 81.7 79.2 76.2 62.3
Sensitivity (%) 3% PEG-CIC 65.3 67.3 67.3 68.3 69.3 72.3 77.2 82.1
Cut-off (ug AIgG equiv. ml-') 310a 300 295 290 280 270 255 215
Accuracy (%) 82.7 81.2 78.7 76.7 75.7 72.8 67.8 60.4
3% PEG-CICs, 3% polyethyene glycol-precipitable circulating immune complexes; AFP, a-fetoprotein. aThe optimal cut-off value selected by
receiver operative characteristic curve.
Table IV Serum a-fetoprotein and circulating immune complexes as diagnostic markers of hepatocellular carcinoma
Marker Sensitivity Specificity Accuracy Predictive value (%) Likelihood ratio
(cut-off value)a (%) (%) (%) Positive Negative Positiveb Negative
A 63.3 100 81.6c 100 73.2 >63 0.36
B 67.3 100 83.6d 100 75.3 >67 0.32
C 65.3 100 82.6 100 74.2 >65 0.34
C or A 83.1 100 91.6c 100 85.5 >83 0.17
C or B 84.1 100 92.Id 100 86.3 >84 0.15
aA, AFP (a-fetoprotein) > 400 ng ml; B, AFP > 120 ngml-'; C, 3% PEG-CICs, (3% polyethylene glycol circulating immune complexes)
3 310isg AIgG equiv. ml-'; bCalculated by using specificity >99%; cp<0.0001; dp<0.O00l.
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_
_
DAFP and CIC as tumour markers of HCC
JF Tsai etal 0
445
(Table IV). Although the area under the ROC curve of AFP
(0.875) was slightly higher than that of 3% PEG-CICs
(0.812), there was no significant difference in the diagnostic
efficiency when either marker was used. When both AFP and
3% PEG-CICs were determined in parallel, 17 (51.5%) of 33
HCC patients with AFP lower than 120 ng ml-' and 20
(54.0%) of 37 HCC patients with AFP lower than
400 ng ml' could be diagnosed. The resulting sensitivity is
83.1% and diagnostic accuracy 91.6% using
AFP = 400 ng ml-' as cut-off point, or a sensitivity of 84.1%
and diagnostic accuracy of 92.1% using AFP = 120 ngml'.
In either condition, the specificity is 100%, with a positive
likelihood ratio greater than 83 and a negative likelihood
ratio between 0.15 and 0.17 (Table IV). As shown in Table
IV, the diagnostic accuracy of using both AFP and 3%
PEG-CICs as markers was significantly higher than using
AFP as marker alone (P<0.0001).
AFP and 3% PEG-CIC levels in relation to tumour size
The echographic patterns of HCCs were classified into diffuse
type (n = 27, 26.7%), nodular type (tumour size <5 cm,
n = 40, 39.6%) and massive type (tumour size > 5 cm,
n = 34, 33.7%). There was no significant difference in the
prevalence of raised AFP (> 120 ngml-') or 3% PEG-CICs
(>310pg AIgG equiv. ml-') between patients with diffuse
HCC and patients with non-diffuse HCC (66.6% vs 67.5%
for AFP and 70.3% vs 63.5% for 3% PEG-CICs). When
tumour size was divided into < 3 cm, >3-5 cm and > 5 cm
in patients with non-diffuse HCC, the prevalence of raised
AFP level was 41.6%, 71.4% and 73.5% respectively. The
frequency of raised 3% PEG-CICs was 50% in tumours
< 3 cm, 64.2% in tumours between 3 and 5 cm and 67.6% in
tumours > 5 cm. The difference is not statistically significant.
These results indicate that there is no relationship between
tumour size (and/or echographic types of tumour) and levels
of AFP and 3% PEG-CICs.
Discussion
The role of the liver in the clearance of immune complexes
has been well established (Hopf et al., 1981). Elevated CICs
in patients with LC, as evidenced in this study (Table I),
might be due to decreased hepatic reticuloendothelial
clearance, which has been shown to be impaired by experi-
mental cirrhosis (Thomas et al., 1973). The 3% PEG-CICs
and 4% PEG-CICs levels were significantly higher in cirr-
hotic patients with HCC than in LC patients alone (Table I).
This implied that both CICs might relate to tumour mass.
However, only 3% PEG-CICs were related, in a
dose-response fashion, to tumour development after adjus-
ting for impaired liver function with multivariate analysis
(Table II). In other words, 3% PEG-CICs may be correlated
with tumour burden (Tsai et al., 1991). Our results of higher
3% PEG-CIC and lower 4% PEG-CIC levels in HCC
patients suggests that the CICs elevated in HCC are larger
than in healthy controls (Zubler et al., 1977) (Table I).
Based on the significant difference in CICs between cirr-
hotic HCC patients and LC patients, an attempt was made
to differentiate HCC from patients with LC by CICs. For
clinical decision making, the selected cut-off value of a
laboratory test should provide the best diagnostic perfor-
mance for either ruling out or ruling in the particular disease.
The ROG curve analysis is a graphic method which can be
used to determine this optimal cut-off level. In addition, it is
a precise and valid measure of diagnostic accuracy (Swets,
1988). In this study, the calculated area under the ROC curve
ofAFP (0.875) and 3% PEG-CICs (0.812) is between 0.7 and
0.9, which indicates that both markers are useful for diagnos-
tic purpose (Swets, 1988).
During recent years various serological markers have been
developed in the diagnosis of HCC (Maussier et al., 1990;
Fujiyama et al., 1992; Kasahara et al., 1993; Sherlock and
Dooley, 1993; Chuang et al., 1994). Serum AFP is among the
most intensively studied tumour markers. Using ROC
analysis, the normal AFP was 5.2 ng ml- (Maussier et al.,
1990). In cirrhotic patients with AFP values higher than
18.5 ngml' the likelihood of HCC being present is 95%
(Maussier et al., 1990). A cut-off value of 150ngml1' for
diagnosis of HCC was suggested previously (Fujiyama et al.,
1992). The diagnostic level of AFP in China is 400ngmlh'
(Chen and Sung, 1977). As shown in this study, AFP levels
less than 400 ngml' were found in 36.6% (37/101) of HCC
patients at the time of tumour detection. It is obvious that
AFP alone is not a reliable indicator for detection of HCC in
patients with a low AFP level. Therefore, additional and
more sensitive diagnostic tools must be sought. In this study,
regardless of which cut-off value (120 ngml' or
400ngml-') was selected, AFP showed a good specificity
(100%) and moderate sensitivity (67.3% or 63.3% respec-
tively) and a high positive likelihood ratio (Table IV). Based
on the selected optimal cut-off value by ROC curve analysis,
3% PEG-CICs showed a high specificity (100%) and
moderate sensitivity (65.3%). However, determination of
AFP and 3% PEG-CICs in parallel significantly increased
the diagnostic accuracy (Table IV). Although each test may
not have sufficient sensitivity, the simultaneous use of both
tests may be highly discriminatory in the detection of HCC.
However, the combined positive predictive value will not be
different from parallel assays if each positive assay is deemed
clinically positive (Table IV). Parallel detection of both
markers increases the number of tests performed, and this
must have cost implications. As the cost of determining 3%
PEG-CICs is low, and the test is easy to perform, the assay
for 3% PEG-CICs should be performed to improve the
detection of HCC in AFP-negative cirrhotics.
Elevation of AFP may be seen in patients with 'active'
liver disease (Chen and Sung, 1977; Sherlock and Dooley,
1993). CICs may also be increased in patients with chronic
liver disease (Brown et al., 1983, 1984; Coursaget et al., 1986;
Tsai et al., 1990a,b, 1991, 1995a-c). Such elevations may
have an important effect upon the specificity of the tests. In
this study, none of the patients with cirrhosis alone had AFP
or 3% PEG-CICs greater than the optimal cut-off points
selected by ROC curve analysis.
The major aim of tumour marker estimation in HCC is as
a means of early detection (surveillance), particularly in the
cirrhotic population. The present analysis has looked at a
population of patients with a histologically proven diagnosis
of HCC. It may be assumed that many of these had
advanced disease and thus a high proportion would have
significantly elevated tumour marker levels. The high
specificity and sensitivity attained might therefore be overes-
timating the value of these tests as a surveillance tool. This
clearly requires further evaluation.
In conclusion, this study shows that addition of an assay
for 3% PEG-CICs to AFP gives a significant improvement in
detection of HCC in patients with cirrhosis. The optimal
cut-off value for AFP in the diagnosis of cirrhotic HCC is
120ILgml-'. In addition, 3% PEG-CICs should be used as
an adjunctive tool in the detection of HCC in cirrhotics
negative for AFP.
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